BACKGROUND Patients with coronary artery disease who undergo stent implantation and have concomitant indication for long term oral anticoagulation represent a considerable percentage of the overall population. To date there is still no consensus about the optimal antithrombotic strategy to choose in this kind of patients, due to the difficult balance between an increased risk of bleeding and thromboembolic complications. Aim of this meta-analysis was to evaluate risk and benefits of triple antihrombotic therapy versus dual antiplatelet therapy in patients undergoing coronary stent implantation, requiring long term oral anticoagulation.
METHODS
We performed formal searches of PubMed, EMBASE, Cochrane central register of controlled trials and major international scientific session abstracts from January 1990 to September 2014 regarding the use of triple antithrombotic therapy versus dual antithrombotic therapy in patients undergoing percutaneous coronary stent implantation that required chronic oral anticoagulation. Data regarding study design, inclusion/exclusion criteria, number of patients, and selected endpoints was extracted by 2 investigators. Disagreements were resolved by consensus.
RESULTS Twelve trials, with a total of 7838 patients undergoing stent implantation with indication to long term oral anticoagulation were finally included. A total of 2686 patients were treated with triple therapy whereas 5152 patients received dual antithrombotic therapy alone. CONCLUSIONS This meta-analysis showed that among patients undergoing coronary stent implantation, requiring chronic oral anticoagulation, the use of a triple antithrombotic therapy is associated with a significant reduction in mortality that largely outweighed the higher risk of major bleeding complications associated with triple therapy. RESULTS In PEGASUS-TIMI 54, 4271 patients had no history of stenting (20%), 8597 had a bare metal stent (BMS, 41%), and 8294 had a drug-eluting stent (DES, 39%). The median time from PCI to randomization was 1.7 yrs (IQR 1.2-2.3; 95% >1 year from PCI). Of the patients with DES, 52% had received either everolimus or zotarolimus-eluting stents (EES or ZES), 27% had received sirolimus or paclitaxel-eluting stents (SES or PES), and stent type was not specified in the remainder. Among patients with stents randomized to placebo, over a median of 33 months of follow-up, recurrent MI was most frequent ischemic event (5.2%), followed by CV death (2.3%) and stroke (1.7%), whereas ARC definite ST was rare (0.7%). Ticagrelor consistently reduced CV death, MI, or stroke regardless of stenting or stent type (pooled ticagrelor vs placebo; Fig Left) with similar magnitude of benefit for each dose and for each of the components.
Rates of definite ST were 0.38% with BMS, 1.01% with SES or PES, and 0.65% with EES or ZES. Ticagrelor 90 mg bid significantly reduced ST whereas there was a trend with ticagrelor 60 mg bid (Fig Right) . The effect was even more pronounced for both doses when patients were on study drug: HR 0.30 (0.14-0.65) & HR 0.66 (0.37-1.17), respectively.
CONCLUSIONS Patients with a history of MI more than 1 year from PCI remain at heightened risk for ischemic events, predominantly MI, CV death, and stroke, with stent thrombosis being rare. Long-term ticagrelor reduces CVD/MI/Stroke regardless of stenting history and reduces stent thrombosis in patients with stents. BACKGROUND Serial follow-up optical coherence tomography (OCT) was used to evaluate the effect of optimal lipid-lowering on qualitative changes in neointimal tissue characteristics after drug-eluting stent (DES) implantation.
METHODS 218 DES-treated patients who received statin therapy were examined with serial follow-up OCT. First and second follow-up OCT evaluations were performed approximately 6 and 18 months after the index procedure. According to the level of low-density lipoprotein cholesterol (LDL-C) measured at the second follow-up, patients were divided into two groups. The optimal lipid-lowering group (n¼121) had an LDL-C reduction of 50%, or an LDL-C level 70mg/dL, and the conventional group (n¼97). Neointimal characteristics were qualitatively categorized as homogeneous vs. non-homogeneous (heterogeneous or layered) patterns using OCT. The qualitative changes of neointimal tissue characteristics between the first and second follow-up OCT examinations were assessed.
RESULTS Between the first and second follow-up OCT procedures, the neointimal cross-sectional area increased more substantially in the conventional group (0.4mm2 vs. 0.2mm2 in the optimal lipid-lowering group, p¼0.01). The neointimal pattern changed from homogeneous to non-homogeneous less often in the optimal lipid-lowering group (1.3%, 1/77, p<0.001) than in the conventional group (15.3%, 11/72, p¼0.44).
Optimal LDL-C reduction was an independent predictor for the prevention of neointimal tissue pattern change from homogeneous to non-homogeneous (odds ratio: 0.04, 95% confidence interval: 0.01w0.41, p¼0.006). CONCLUSIONS In conclusion, this serial OCT study suggests that an intensive reduction of LDL-C could prevent the non-homogeneous change of the neointima and the increase in neointimal crosssectional area compared with the conventional LDL-C control.
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